Raymond James initiated coverage on shares of Ionis Pharmaceuticals ( NASDAQ:IONS – Free Report ) in a research note published on Thursday, MarketBeat.com reports. The brokerage issued a strong-buy rating and a $63.00 target price on the stock. Other analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a buy rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday. Morgan Stanley upped their target price on shares of Ionis Pharmaceuticals from $42.

https://www.dailypolitical.com/2023/10/01/raymond-james-begins-coverage-on-ionis-pharmaceuticals-nasdaqions.html

#dailypolitical